Atgam
Generic name:equine thymocyte immune globulin
Dosage form: injection, solution
Drug class:Selective immunosuppressants
Medically reviewed by Drugs.com. Last updated on Aug 1, 2021.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- References
- How Supplied/Storage and Handling
- Patient Counseling Information
Antithymocyte globulins can cause anaphylaxis when injected intravenously. Although Atgam is processed to reduce the level of antibodies that will react to non-T cells, physicians should be prepared for the potential risk of anaphylaxis and monitor patients for signs and symptoms during infusion.
Indications and Usage for Atgam
Renal Allograft Rejection
Renal transplant rejection: Atgam is indicated for the management of allograft rejection in renal transplant patients; when administered with conventional therapy at the time of rejection Atgam increases the frequency of resolution of the acute rejection episode [see Clinical Studies (14.1)].
Aplastic Anemia
Atgam is indicated for the treatment of moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation [see Clinical Studies (14.2)].
The usefulness of Atgam has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation.
Atgam Dosage and Administration
Atgam is intended for intravenous use only.
Atgam is used with concomitant immunosuppressants. During repeat courses of Atgam,...
